Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety concerns
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators.
